Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Variational AI is using its Enki platform to explore uncharted regions of the chemical space, accelerating the discovery and development of transformative therapeutics in collaboration with biopharma partners across various high-need therapeutic areas.
ExploRNA Therapeutics’ biologically inspired, ground-breaking technologies are enabling more precise customization of mRNA constructs with advanced vaccine and therapeutic applications.
Powered by its industry-leading library of genomic data, covering a comprehensive spectrum of genes, Caris Life Sciences is committed to identifying the best treatments.
The Korea Drug Development Fund (KDDF), Korea’s largest non-dilutive funder of drug research and development (R&D), is advancing Korea’s oncology sector with a globally competitive, modality-diverse pipeline of cancer therapeutics.
By detecting and targeting myeloid-dependent immune suppression, Bectas Therapeutics is on a mission to realize the full potential of cancer immunotherapies.
Actithera is pioneering chemistries in radioligand therapy that extend tumor residence time, creating differentiated candidates like its lead fibroblast activation protein-targeted compound.
Adverum Biotechnologies is developing one-time gene therapies aimed at revolutionizing the treatment of patients with wet age-related macular degeneration and other serious ocular disorders.
Candel Therapeutics is driving a paradigm shift in the treatment of solid tumors through the development of novel viral immunotherapies. The company plans to file a Biologics License Application (BLA) for its lead clinical candidate, aglatimagene besadenovec (CAN-2409), for localized prostate cancer in late 2026.
Angiocrine Bioscience uses its propriety platform to harness the reparative powers of vascular endothelial cells and develop advanced therapeutics that repair tissue damage and treat chronic conditions.
DC-Biotech is using its pioneering, proprietary αNKT technology to leverage the unique immunomodulatory properties of natural killer T-cells and mesenchymal stem cells, accelerating the development of regenerative medical products for diseases with unmet need, particularly those related to immune system dysregulation and inflammation.
Biotech firm Syntax Bio aims to transform pluripotent stem cells into clinical therapeutics using its CRISPR-based technology platform called Cellgorithm.
NodThera has developed first-in-class small-molecule inhibitors of the NLRP3 inflammasome, a master switch for inflammation, and is charting a clinical path to patients in multiple indications.
NanoSyrinx is pioneering Nanosyringe technology for targeted intracellular delivery of proteins, a new modality enabling access to undruggable targets and redefining what is possible for biologics.
NEOsphere Biotechnologies is accelerating drug discovery through high-throughput proteomics, enabling efficient screening of molecular glue libraries and systematic identification of clinically relevant degraders.
Defence Therapeutics’ proprietary Accum technology platform reduces the half-maximal inhibitory concentration (IC50) of antibody–drug conjugates up to fifty-fold by solving the endosome-entrapment problem.
The government-funded organization supports Korean biotech and pharma companies in more than 100 pipelines annually to discover, develop and test the most promising therapeutic candidates.
